What Does Rigenera® Technology Platform Cost?

Realistic pricing for the autologous micrograft generation system, from hardware to disposables

Rigenera® is a Class I medical device with CE and FDA certification that allows the preparation of microinstructions through a mechanical process for tissue regeneration treatments. However, published list prices and transparent equipment quotes for the full Rigenera® system remain difficult to verify from manufacturer sources. This article summarizes what procurement officers can expect based on device components, market evidence, and indirect sources.

What the typical range is

No manufacturer list price is publicly available. Third-party resellers and equipment brokers show implied pricing for comparable autologous tissue processors in the $2,200–$2,600 range (single units from India-based sellers with free shipping). One European aesthetic equipment distributor lists a related multi-technology device at €12,000 (~$13,000 USD), though that model combines Rigenera technology with radiofrequency and vacuum massage—not a pure tissue processor.

Clinician-facing treatment pricing—which reflects system depreciation, consumable costs, and service—averages $2,000–$3,500 per session across hair loss clinics using Rigenera Activa protocols. This suggests the base equipment carries a lower capex cost relative to traditional tissue banking systems, but consumable and service fees dominate long-term budget impact.

What pushes price up—features, certifications, support tier

Rigenera's main product line consists of Class IIa medical devices that facilitate the regeneration of various bio-tissues through a minimally invasive procedure that utilizes micro-grafts. The newer Rigenera N4SA 2.0®, a Class I medical device, uses two specialized attachments: Rigeneracons Derma® for stem cell injections and Adipecons® for creating solutions during hair transplant surgery.

Higher-capacity versions cost more. Technical improvements over basic models include a bigger grid surface that can hold up to 20 skin biopsies for disaggregation, and the volume of AMT solution obtained increases to 16 ml (vs. 1.5 ml in the Derma-only version). Premium configurations intended for hair transplant surgeons—where volume throughput justifies capital investment—command price premiums.

Regulatory clearance in target markets adds cost. Rigenera® is a Class I medical device manufactured in Italy by HBW, worldwide patented and marketed all over the world. The Rigenera® system has been utilised since 2013 and in recent years it is becoming increasingly successful in the European and International countries. Establishing FDA and CE marks (which the platform holds) requires validation studies and dossier preparation—costs typically borne by manufacturers but sometimes passed to early-market buyers.

Training and clinical certification tiers. Rigenera® technology is used by more than 10,000 doctors worldwide, and over 450,000 treatments have been performed with it. Vendors increasingly bundle hands-on training and credentialing; premium tiers include on-site installation and multi-clinician certification, adding $5,000–$15,000 to total acquisition cost.

What pushes price down—refurbished, older generation, lease, GPO contracts

Older hardware generations: Early Rigenera systems (pre-N4SA 2.0) process smaller tissue samples and yield lower micrograft volumes. Used markets show these units at 25–40% discounts compared to new models.

Lease and per-use models: Some vendors and clinic networks are moving to leased equipment or per-procedure kits, avoiding large upfront capital. Consumable costs dominate—each use requires a disposable Rigeneracons (Class IIa) or Adipecons, estimated at $150–$300 per use based on sterilization and manufacturing complexity.

Volume purchasing: Established hair restoration networks and plastic surgery groups with high patient throughput can negotiate bundled pricing on disposables—potentially reducing per-use cost to $100–$150 per micrograft extraction.

International sourcing: Similar machines marketed as "comparable AMT systems" or "progenitor cell processors" from Indian manufacturers enter secondary markets at 30–50% below European/Italian OEM pricing, but lack CE/FDA verification, clinical support, and spare-parts supply chains.

Hidden costs—install, training, calibration, consumables, service contracts

Disposable consumables dominate lifecycle cost. Rigeneracons® Derma is a disposable Class IIa Medical Device that provides about 1.5 ml of filtered and concentrated micro-grafts as injectable solutions, recommended for hair and skin protocols. At 1–3 uses per patient and typical session pricing of $2,000–$3,500, consumables represent 60–75% of the true cost of care per treatment.

Training and certification (2–4 weeks): On-site and online training programs range from $3,000–$8,000. Certification requires documented clinical competency; some vendors require annual recertification.

Service and maintenance (annual): No standardized warranty structure is public, but implied support agreements (based on aesthetic device norms) run $2,000–$4,000/year. Rigenera devices are mechanical—low failure rate—but repairs require manufacturer involvement or authorized service centers.

Installation and site preparation: Minimal electrical/space requirements (rotary centrifuge, standard operating room table). Installation typically under $1,500.

Quality assurance and validation: Clinics must establish standard operating procedures (SOPs), validate output (micrograft viability counts), and document lot traceability. RFID chips embedded in single-use kits aid this, but internal labor cost is $5,000–$10,000 in year one.

How to negotiate—concrete tactics

1. Benchmark against consumable cost: Lock in per-unit pricing for Rigeneracons Derma and Adipecons at the outset. Bulk-quantity discounts typically kick in at 100+ units/year; negotiate 5–15% reductions.

2. Separate capex from service: Negotiate equipment purchase, training, and annual support as distinct line items. Some vendors inflate hardware cost while offering "free" first-year support; push back to itemize.

3. Clarify warranty scope: Confirm coverage for mechanical failure (rotary motor, housing) vs. cosmetic/wear items. Request 2-year parts warranty at minimum.

4. Request clinical data: Ask vendors for outcomes data from comparable clinics (hair density recovery, patient satisfaction) and comparative efficacy vs. PRP or other autologous systems. Clinical studies report that between 80-90% of patients show a great improvement in hair density and quality.

5. Explore lease-to-own: For clinics with uncertain volume forecasts, lease options spread risk; total cost of ownership often within 10–20% of purchase.

6. Demand training for all staff roles: Don't accept single-operator training. Require tissue procurement staff, operating room nurses, and injection clinicians all receive certification.

When the price feels off—red flags

• No service agreement in writing. If a vendor quotes equipment without mentioning support, maintenance, or consumable pricing, walk. Hidden service costs can double TCO.
• Vague consumable pricing. "Kits sold separately" without per-unit quotes suggests variable or undisclosed mark-ups. Lock in volume pricing before commitment.
• Claims of "FDA approval" for off-label uses. Despite the general lack of specific approval by the U.S. Food and Drug Administration (FDA), the treatment follows international guidelines for safety and efficacy. The device is cleared; the clinical applications are not universally cleared for all indications. Confirm intended use statement matches your clinical protocol.
• Implied retraining fees for software/firmware updates. Legitimate updates should be free; recurring "certification" fees are often vendor lock-in tactics.
• Comparable "clones" marketed at 50%+ discounts. While some legitimate competition exists, unverified devices lack clinical evidence, parts support, and regulatory standing. Risk of supply chain disruption outweighs capex savings.

Sources

Rigenera HBW is a company focused on regenerative medicine, offering advanced technology for tissue regeneration within the medical device sector. Their main product line consists of Class IIa medical devices that facilitate the regeneration of various bio-tissues through a minimally invasive procedure that utilizes micro-grafts. The company primarily serves sectors such as wound care, plastic surgery, orthopedics, and oral surgery.

• Technical specifications: Regenera Activa Worldwide (rigeneraactiva.com), Rigenera HBW product documentation
• Clinical evidence: Frontiers in Bioengineering (2022); Skin Appendage Disorders, Karger (2025); MDPI Applied Sciences (2020)
• Regulatory status: FDA 510(k) records; CE Technical File documentation
• Third-party pricing: eBay marketplace listings (new India-sourced systems); EMS-Beauty Europe distributor (€12,000)
• Clinical outcomes: Absolute Hair Clinic, DHI International, Dynamic Regenerative Medicine (patient-reported session pricing: $2,000–$3,500 USD equivalent)

Note: This article reflects pricing and data as of May 2026. MedSource does not yet have aggregate institutional purchase quotes for Rigenera® platforms. Procurement officers are encouraged to request formal quotes from HBW directly or authorized regional distributors, as public list prices remain unavailable. This article will be updated as market quote data accumulates.